TP53 and breast carcinoma: The results validated that HDAC2 knockdown could suppress cell proliferation of HCT116 cells, which was consistent with findings in breast cancer, in which the knockdown of HDAC2 has been proven to inhibit cell proliferation by increasing the binding activity of p53 (29).